Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases

Over 10 million doses of COVID‐19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide. Although generally very safe, post‐vaccine myocarditis can result from adaptive humoral and cellular, cardiac‐specific inflammation within d...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidecker, Bettina, Dagan, Noa, Balicer, Ran, Eriksson, Urs, Rosano, Giuseppe, Coats, Andrew, Tschöpe, Carsten, Kelle, Sebastian, Poland, Gregory A., Frustaci, Andrea, Klingel, Karin, Martin, Pilar, Hare, Joshua M., Cooper, Leslie T., Pantazis, Antonis, Imazio, Massimo, Prasad, Sanjay, Lüscher, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Clinical Consensus Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538893/
https://www.ncbi.nlm.nih.gov/pubmed/36065751
http://dx.doi.org/10.1002/ejhf.2669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538893/
https://www.ncbi.nlm.nih.gov/pubmed/36065751
http://dx.doi.org/10.1002/ejhf.2669

Ejemplares similares